Q2
AMGN — Q2 2026 Financial Report Analysis
Amgen grew product sales 9% to $9.5 billion on volume in Q2 2026 and raised full-year guidance, but its 65% jump in reported EPS is mostly Horizon acquisition amortization rolling off — adjusted EPS rose 4%, and guidance implies second-half revenue growth slowing to about 4% as Prolia and XGEVA biosimilar erosion accelerates.